Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011407:Propane / Q000008:administration & dosage / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010879:Piperazines; D004317:Doxorubicin; D002945:Cisplatin; D011407:Propane; D003630:Daunorubicin